3ème étage 262
Rue du Faubourg Saint-Honore
Paris 75008
France
33 1 85 73 36 20
https://www.advicenne.com
Secteur(s): Healthcare
Secteur d’activité: Biotechnology
Employés à temps plein: 21
Nom | Titre | Payer | Exercé | Année de naissance |
---|---|---|---|---|
Mr. Didier Laurens | CEO, MD, General Director & Director | 181,84k | S.O. | 1967 |
Mr. Laurent Cassedanne | Deputy CEO, Deputy GM & Head Pharmacist | 152,74k | S.O. | S.O. |
Isabelle Kervella | Chief Financial Officer | S.O. | S.O. | S.O. |
Dr. André Ulmann M.D., Ph.D. | Chief Medical Officer & Non-Voting Director | S.O. | S.O. | 1950 |
Ms. Hege Hellstrom | Chief Commercial Officer | S.O. | S.O. | 1965 |
Advicenne S.A., a specialty pharmaceutical company, develops, commercializes, and markets treatments for rare renal diseases. Its main drug candidate is Sibnayal, which has completed phase III clinical trial for the treatment of distal renal tubular acidosis, as well as cystinuria. The company also distributes Likozam, a formulation of clobazam for the treatment of short-term symptomatic of severe, disabling, or condition-causing anxiety unacceptable distress; and Levidcen, a galenic form of levetiracetam for the treatment of epileptic seizures. Advicenne S.A. was incorporated in 2007 and is headquartered in Paris, France.
L’ISS Governance QualityScore de Advicenne S.A. en date du S.O. est S.O.. Les scores principaux sont Audit : S.O.; Société : S.O.; Droits des actionnaires : S.O.; Compensation : S.O..